Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Symbio Pharmaceuticals Ltd Discontinues Phase II Trial in Multiple Myeloma


Friday, 1 Nov 2013 03:30am EDT 

Symbio Pharmaceuticals Ltd announced that it has decided to discontinue its phase II clinical trial in Japan for TREAKISYM (bendamustine HCI, SyB L-0501) in refractory and relapsed multiple myeloma (r/r MM). discontinue its phase II clinical trial in Japan for TREAKISYM (bendamustine HCI, SyB L-0501) in refractory and relapsed multiple myeloma (r/r MM). In collaboration with Eisai (Headquarters: Tokyo, "Eisai"), SymBio had been conducting the multicenter open-label trial in r/r MM patients with bendamustine as a monotherapy since December, 2011, as it continues to pursue the approval of additional indications for TREAKISYM. While safety of the drug has been established in this study following the treatment of 17 patients at 90 mg/m2, the study has failed to achieve the expected level of efficacy as a single agent. 

Latest Key Developments in Pharmaceuticals

Company Quote

264.0
-8.0 -2.94%
11 Jul 2014